Altogether, this study reveals a previously unrecognized role of HOXC10 in pan-KRAS-mutant lung cancer bone metastasis, and suggests HOXC10 as a therapeutic target for treating this intractable disease. This evidence concerns the gene KRAS and lung carcinoma.